A guideline should always be seen as an educational device. Guidelines are prepared by a panel of experts on the field based on a critical review of the quality of available evidence. Guidelines are used to assist endoscopists while providing the standard of care to patients and should not be used as a rule. However, the question remains: are all guidelines useful or equivalent in quality?
Gallstone disease is a common clinical problem. In Europe, ultrasound studies revealed a prevalence of 9-21% and an incidence of 0.63/100 persons/year [1] [2] [3] [4] . Choledocholithiasis or common bile duct (CBD) stones are a frequent complication of gallstone disease and are pres-stones [4] . The guideline classifies patients into high risk (>50%), intermediate risk (10-50%) , and low risk of choledocholithiasis (<10%) as far as the probability of having CBD stones is concerned. Patients at high risk were defined as having any of the very strong predictors of choledocholithiasis (i.e., CBD stones on transabdominal US, clinical ascending cholangitis, or serum bilirubin level >4 mg/dL) or both strong predictors (i.e., dilated CBD on US, namely >6 mm with gallbladder in situ, and bilirubin level 1.8-4 mg/dL). Patients at intermediate risk were those with the presence of 1 strong predictor or any moderate predictor (abnormal liver biochemical tests other than bilirubin, age older than 55 years, and clinical gallstone pancreatitis). Patients with low risk were those with no predictors present. Based on these guidelines, patients at high risk should directly receive ERCP, patients at intermediate risk should be submitted to less invasive evaluations, namely preoperative MRCP or EUS or as an alternative an intraoperative fluorocholangiography (IOFC), and, finally, patients at low risk could directly go on to laparoscopic cholecystectomy without the need for IOFC. However, before further analysis of the literature after the release of these guidelines, the reader should keep in mind the following issues: (a) guidelines are educational devices that may assist endoscopists in taking decisions and not rules; (b) clearly, the ASGE guidelines define patients with >50% probability of having a CBD stone as being at high risk; (c) these guidelines were issued with the goal of reducing the overuse of ERCP and, therefore, of increasing patients' safety, and (d) they were issued to minimize the number of unnecessary radiologic procedures, which have been associated with excessive expenditures, and, therefore, guidelines should also be evaluated from a perspective of cost-effectiveness [13] .
After the release of the ASGE guidelines, several investigators tried to validate them in the clinical scenario. In one study from the USA, 179 patients with ASGE highrisk probability criteria were retrospectively analyzed, and 99 (56.3%) of these patients had a stone/sludge on subsequent confirmation test; therefore, almost 50% of these patients were submitted to unnecessary ERCP [14] . The overall accuracy of the guidelines was, in this study, 62.1% (47.4% sensitivity and 73% specificity). In Spain, a prospective study analyzed 256 patients with suspected choledocholithiasis [3] . Of the 208 patients with high-risk probability criteria for CBD stones, 124 (59.6%) patients were found to have a stone/sludge on ERCP, providing an overall accuracy of 59.0% (85.5% sensitivity and 24.3% specificity). The remaining 48 patients had an intermediate probability of CBD stones, and only 21 (43.8%) had a stone/sludge, providing an accuracy of 41.0% (14.4% sensitivity and 75.6% specificity). Another study prospectively observed 336 patients with suspected choledocholithiasis [15] . Of the 244 patients with a high-risk probability of CBD stones, 185 (75.8%) were found to have stones on ERCP (accuracy of 69.05%). Of the 92 patients with an intermediate risk for choledocholithiasis, 45 (48.9%) had stones on ERCP (accuracy 39.95%). Another study from the USA retrospectively analyzed 71 patients which met ASGE high-risk probability criteria for CBD stones [16] . Of these, only 39 (54%) were found to have a stone on ERCP. Overall, in this study, the accuracy of the guidelines was 63% (sensitivity 54.9% and specificity 68.6%). In China, the largest published series included 1,171 patients with high-risk criteria [5] . Of these 1,171 patients, definitive testing (MRCP, EUS, IOFC, and ERCP) revealed CBD stones in 1,076 (40%) patients (70% sensitivity and 74.3% specificity).
Taken together, the published studies show that the guidelines performed exactly as they were intended to perform. I remember that patients at high risk were defined as having a probability of choledocholithiasis >50%. Published series reported that patients with high-risk criteria for CBD stones had a documented stone/sludge in a range between 40 and 79.8% (average 60.1%) of the ERCPs [2, 3, 5, [14] [15] [16] . The majority of the published series concluded that the ASGE criteria demonstrated a probability of >50% of the patients having CBD stones. However, authors should also consider that the ASGE guidelines performed suboptimally, and the application of the current guidelines would lead to unnecessary diagnostic ERCPs in more than one-third of the patients, which is not acceptable [2, 3, 5, [14] [15] [16] .
One issue that has not been systematically tested is the application of the ASGE guidelines in patients with acute cholecystitis. It is important to remember that the abovementioned guidelines were not developed nor validated for patients with acute cholecystitis. Furthermore, patients with acute cholecystitis have elevated liver enzymes and elevated bilirubin (sometimes >4 mg/dL), which can be conflicting for the diagnosis of CBD stones [17] , and abdominal ultrasound can be associated with a poorer detection rate of CBD stones in these patients [18] . In this issue of GE -Portuguese Journal of Gastroenterology , Gouveia et al. [19] retrospectively analyzed 4,369 patients with acute cholecystitis, and only 40 (0.92%) patients had a clinical or a sonographic suspicion of choledocholithiasis, which is not in line with the reported literature, where patients with acute cholecystitis have CBD stones in rates ranging from 9 to 58% [17, 18] . As this was a retrospective analysis, we can always raise the question if the patients were correctly encoded for the diagnosis of acute cholecystitis. Further, the low number of patients included limited the strength of the analysis and our conclusions. Nonetheless, 31 patients had ASGE high-probability criteria for CBD stones and 9 had an intermediate risk. Not surprisingly, of the 31 patients with high-risk criteria, only 16 (51.6%) patients were found to have CBD stones, providing an accuracy of 57%, and these values were well in line with the published literature. However, in the study of Gouveia et al. [19] , the specificity was 31.8% and the positive predictive value 52%, which are lower values than those previously published and suggest that in this group of patients (acute cholecystitis) the ASGE guidelines perform even poorer than in the usual clinical scenario. Interestingly, and when using only the liver function tests (LFTs) in patients with acute cholecystitis, we found conflicting results in the literature. In a study from Sweden, when using LFTs as predictors of choledocholithiasis in patients with acute cholecystitis, the authors found a positive predictive value of 9% [17] . However, in a recent paper from Korea, the authors analyzed patients with acute cholecystitis which were divided into 2 groups (with and without CBD stones) [20] . They analyzed LFT values on initial admission and the changes of LFT values over time after admission. Of all the LFT variables analyzed, γ-glutamyl transpeptidase was the most reliable variable for predicting the presence of CBD stones, with a sensitivity of 80.6% and a specificity of 75.3% at the cutoff level of 224 IU/L. Finally, the authors concluded that the LFT values on initial admission and the changes in LFT values over time are reliable predictors of CBD stones in patients with acute cholecystitis.
In conclusion, the ASGE guidelines may lead to an unnecessarily large number of ERCPs, which can be associated with complications. Further, in the scenario of acute cholecystitis, the ASGE guidelines have a low positive predictive value and specificity and, therefore, perform poorer in the above-mentioned group of patients, leading to an excessive overuse of ERCP as described in the paper of Gouveia et al. [19] . It is clear that the ASGE guidelines should be re-opened for discussion. The optimal cost-effectiveness approach for patients with suspected CBD stones is unknown, but new modalities should be used. He et al. [5] suggest that a revised algorithm with more stringent criteria that includes choledocholithiasis on abdominal US and/or bilirubin levels >4 mg/dL plus CBD dilation on abdominal US may improve patient selection and reduce the risk of diagnostic ERCP. However, in the clinical scenario, most of the authors [3, 5, [14] [15] [16] , including myself, advocate the use of alternative diagnostic strategies for all patients with high and intermediate probability of choledocholithiasis, namely MRCP or EUS before ERCP. The ASGE guidelines should be used carefully because they are not a fairy tale for sure, and a lifethreatening complication of a diagnostic ERCP is always a nightmare.
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